Day One Biopharmaceuticals (NASDAQ:DAWN) Trading 3.8% Higher

Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN - Get Free Report) shares shot up 3.8% during trading on Tuesday . The company traded as high as $14.44 and last traded at $14.38. 233,012 shares were traded during mid-day trading, a decline of 62% from the average session volume of 608,511 shares. The stock had previously closed at $13.85.

Wall Street Analyst Weigh In

A number of brokerages have commented on DAWN. Oppenheimer restated a "market perform" rating on shares of Day One Biopharmaceuticals in a research report on Tuesday, February 27th. The Goldman Sachs Group cut their target price on Day One Biopharmaceuticals from $50.00 to $44.00 and set a "buy" rating for the company in a research report on Tuesday, February 27th. Finally, Piper Sandler reiterated an "overweight" rating and set a $40.00 target price on shares of Day One Biopharmaceuticals in a research report on Tuesday, March 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company's stock. Based on data from MarketBeat, Day One Biopharmaceuticals has a consensus rating of "Moderate Buy" and a consensus target price of $40.60.

Day One Biopharmaceuticals Price Performance

The firm has a 50-day moving average of $15.26 and a 200-day moving average of $13.64. The stock has a market cap of $1.28 billion, a PE ratio of -6.11 and a beta of -1.48.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its quarterly earnings results on Monday, February 26th. The company reported ($0.64) EPS for the quarter, missing analysts' consensus estimates of ($0.57) by ($0.07). Equities analysts forecast that Day One Biopharmaceuticals, Inc. will post -2.66 EPS for the current fiscal year.

Insider Activity at Day One Biopharmaceuticals

In related news, CFO Charles N. York II sold 2,666 shares of the stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $15.25, for a total transaction of $40,656.50. Following the completion of the transaction, the chief financial officer now directly owns 277,754 shares of the company's stock, valued at $4,235,748.50. The sale was disclosed in a filing with the SEC, which is available through this link. In other news, insider Samuel C. Blackman sold 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 27th. The stock was sold at an average price of $16.11, for a total value of $322,200.00. Following the completion of the sale, the insider now directly owns 1,224,662 shares of the company's stock, valued at approximately $19,729,304.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Charles N. York II sold 2,666 shares of the firm's stock in a transaction that occurred on Friday, February 16th. The shares were sold at an average price of $15.25, for a total value of $40,656.50. Following the completion of the sale, the chief financial officer now directly owns 277,754 shares of the company's stock, valued at $4,235,748.50. The disclosure for this sale can be found here. Over the last three months, insiders sold 45,781 shares of company stock valued at $722,960. Insiders own 8.40% of the company's stock.

Institutional Investors Weigh In On Day One Biopharmaceuticals

Several institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Day One Biopharmaceuticals by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 4,769,746 shares of the company's stock valued at $69,638,000 after purchasing an additional 139,992 shares during the last quarter. Fisher Asset Management LLC lifted its stake in shares of Day One Biopharmaceuticals by 89.0% during the 4th quarter. Fisher Asset Management LLC now owns 68,446 shares of the company's stock worth $999,000 after acquiring an additional 32,238 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Day One Biopharmaceuticals by 77.7% during the 4th quarter. Wellington Management Group LLP now owns 208,969 shares of the company's stock worth $3,051,000 after acquiring an additional 91,393 shares during the last quarter. Goldman Sachs Group Inc. lifted its stake in shares of Day One Biopharmaceuticals by 28.7% during the 4th quarter. Goldman Sachs Group Inc. now owns 2,118,849 shares of the company's stock worth $30,935,000 after acquiring an additional 472,654 shares during the last quarter. Finally, Quintet Private Bank Europe S.A. lifted its stake in shares of Day One Biopharmaceuticals by 43.2% during the 4th quarter. Quintet Private Bank Europe S.A. now owns 3,313 shares of the company's stock worth $48,000 after acquiring an additional 1,000 shares during the last quarter. 87.95% of the stock is owned by institutional investors.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.